Stockscreener 앱 받기
26.35
0.92%
0.217
전일 마감가:
$26.13
열려 있는:
$26.14
하루 거래량:
1.03M
Relative Volume:
0.60
시가총액:
$4.34B
수익:
$1.51B
순이익/손실:
$333.35M
주가수익비율:
13.51
EPS:
1.95
순현금흐름:
$315.22M
1주 성능:
-1.09%
1개월 성능:
-8.47%
6개월 성능:
-15.62%
1년 성능:
-5.42%
1일 변동 폭
$26.14
$26.52
1주일 범위
$26.05
$27.24
52주 변동 폭
$25.56
$36.45
Alkermes Plc Stock (ALKS) Company Profile
명칭
Alkermes Plc
전화
00-353-1-772-8000
주소
CONNAUGHT HOUSE, DUBLIN 4
ALKS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ALKS
Alkermes Plc
|
26.34 | 4.31B | 1.51B | 333.35M | 315.22M | 1.95 |
|
ZTS
Zoetis Inc
|
151.82 | 67.73B | 9.29B | 2.52B | 2.28B | 5.57 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.31 | 45.73B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
HLN
Haleon Plc Adr
|
9.725 | 44.38B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.48 | 18.97B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
299.44 | 13.73B | 2.99B | 1.21B | 1.13B | 25.06 |
Alkermes Plc Stock (ALKS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-15 | 개시 | Goldman | Buy |
| 2025-06-17 | 업그레이드 | UBS | Neutral → Buy |
| 2025-05-28 | 개시 | Needham | Buy |
| 2025-03-13 | 개시 | RBC Capital Mkts | Sector Perform |
| 2025-03-04 | 업그레이드 | UBS | Sell → Neutral |
| 2025-02-11 | 개시 | Deutsche Bank | Buy |
| 2024-11-05 | 업그레이드 | Stifel | Hold → Buy |
| 2024-06-17 | 개시 | TD Cowen | Buy |
| 2024-03-19 | 개시 | Robert W. Baird | Outperform |
| 2024-02-20 | 다운그레이드 | UBS | Neutral → Sell |
| 2023-11-20 | 재개 | JP Morgan | Neutral |
| 2023-10-24 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2023-10-17 | 개시 | UBS | Neutral |
| 2022-11-03 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2022-10-14 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2022-08-16 | 개시 | Piper Sandler | Neutral |
| 2022-04-22 | 재개 | Goldman | Buy |
| 2022-04-20 | 개시 | Goldman | Buy |
| 2022-01-27 | 업그레이드 | Cantor Fitzgerald | Hold → Overweight |
| 2021-12-01 | 개시 | Citigroup | Neutral |
| 2021-10-07 | 업그레이드 | Jefferies | Hold → Buy |
| 2021-09-02 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2020-10-15 | 업그레이드 | Mizuho | Neutral → Buy |
| 2020-07-30 | 다운그레이드 | Goldman | Neutral → Sell |
| 2020-02-14 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2020-02-14 | 재확인 | H.C. Wainwright | Neutral |
| 2020-02-14 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-02-06 | 개시 | Mizuho | Neutral |
| 2020-01-31 | 업그레이드 | Wolfe Research | Underperform → Peer Perform |
| 2019-09-05 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2019-07-15 | 업그레이드 | Goldman | Sell → Neutral |
| 2019-05-31 | 개시 | H.C. Wainwright | Neutral |
| 2019-05-01 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2018-12-19 | 다운그레이드 | Goldman | Neutral → Sell |
| 2018-12-14 | 개시 | Wolfe Research | Underperform |
| 2018-12-13 | 다운그레이드 | Credit Suisse | Outperform → Underperform |
| 2018-11-05 | 개시 | Piper Jaffray | Neutral |
| 2018-08-07 | 개시 | Stifel | Hold |
| 2018-06-21 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2018-06-06 | 개시 | B. Riley FBR, Inc. | Buy |
| 2018-05-16 | 업그레이드 | Citigroup | Neutral → Buy |
| 2018-05-11 | 개시 | BofA/Merrill | Buy |
모두보기
Alkermes Plc 주식(ALKS)의 최신 뉴스
Does Alkermes plc stock perform well during market downturnsEntry Signal Watchlist With High Returns - jammulinksnews.com
What are analysts’ price targets for Alkermes plc in the next 12 monthsFree Market Volatility Navigation Tips - jammulinksnews.com
Is Alkermes plc Stock Overbought or Oversold RSI Indicator AnalysisCapital Efficient Investment Tips - metal.it
What catalysts could drive Alkermes plc stock higher in 2025Phenomenal trading returns - jammulinksnews.com
Is Alkermes plc a growth stock or a value stockUnlock steady growth with low-risk stocks - jammulinksnews.com
What drives Alkermes plc stock priceSuperior capital gains - Autocar Professional
Alkermes plc (NASDAQ:ALKS) Launches Phase II Trial of ALKS 2680 for Idiopathic Hypersomnia - MSN
Abivax’s miRNA therapy emerges as a new mechanism for ulcerative colitis - BioCentury
Goldman Sachs Initiates Alkermes (ALKS) with a Buy Rating - MSN
What analysts say about Alkermes plc stockHigh-yield portfolio picks - Autocar Professional
Alkermes plc Stock Analysis and ForecastSuperior investment outcomes - jammulinksnews.com
Is Alkermes plc a good long term investmentFree Wealth Planning Blueprint - jammulinksnews.com
ALKS Down Despite Positive Top-Line Data From Narcolepsy Study - The Globe and Mail
Alkermes (ALKS) Expected to Beat Earnings Estimates: Should You Buy? - Yahoo Finance
Alkermes stock holds steady as H.C. Wainwright maintains Neutral rating By Investing.com - Investing.com UK
Alkermes Announces Positive Phase 2 Study Results - TipRanks
Oversold Conditions For Alkermes (ALKS) - Nasdaq
Alkermes To Advance Alixorexton After Positive Phase II Narcolepsy Results - insights.citeline.com
Jefferies Raises Target for Alkermes (ALKS) Following Promising Drug Data | ALKS Stock News - GuruFocus
Why Alkermes Tumbled On Its Positive Narcolepsy Study - inkl
Alkermes Oral Drug Helps Patients Stay Awake In Mid-Stage Sleep Disorder Study - inkl
Why Is Alkermes Stock Falling On Monday?Alkermes (NASDAQ:ALKS) - Benzinga
Alkermes stock falls after BofA maintains Neutral rating on narcolepsy drug - Investing.com UK
Alkermes narcolepsy drug headed for late-stage testing - BioPharma Dive
Needham & Company LLC Reaffirms Buy Rating for Alkermes (NASDAQ:ALKS) - MarketBeat
Alkermes stock rating reiterated as Buy by Stifel after positive narcolepsy data - Investing.com UK
Alkermes Vibrance-1 Phase 2 Study Of Alixorexton In Narcolepsy Type 1 Meets Primary Goal - Nasdaq
Alkermes narcolepsy drug shows positive results in phase 2 trial By Investing.com - Investing.com Nigeria
Alkermes narcolepsy drug shows positive results in phase 2 trial - Investing.com
Alkermes announces positive topline results from Vibrance-1 Phase 2 study - MarketScreener
Alkermes Announces Positive Topline Results From Vibrance-1 Phase 2 Study of Once-Daily Alixorexton in Patients With Narcolepsy Type 1 - Finansavisen
Alkermes Orexin Receptor Agonist Shows Broad Benefits in Phase 2 Narcolepsy Study - Sleep Review
Is Alkermes Plc's (NASDAQ:ALKS) Latest Stock Performance Being Led By Its Strong Fundamentals? - 富途牛牛
10 Most Undervalued Pharma Stocks to Buy Now - Insider Monkey
Alkermes Plc (ALKS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Alkermes Plc 주식 (ALKS) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Nichols Christian Todd | SVP, Chief Commercial Officer |
Jun 10 '25 |
Sale |
31.09 |
3,334 |
103,654 |
86,208 |
0.07%
0.57%
자본화:
|
볼륨(24시간):